Primary Image

Generic Background Image

Clinical Trial

T Cell-Mediated Autoimmune Responses in Parkinson’s Disease

IRB Protocol Number STU00209668

Contact

Douglas Merkitch dmerkitch@sralab.org

Objective

This study aims to further examine a type of T cell, an immune cell in the blood, found to appear in about half of people with Parkinson’s disease (PD) and only rarely in age-matched control volunteers. This type of T-cell may be a biomarker of PD. A biomarker is a substance or characteristic in our bodies that is associated with the presence of disease or that changes over time in a way that can be linked to the progression of disease. These biological measures will help develop treatments for Parkinson’s, particularly therapies that could slow or stop progression.

Who Can Participate

People with Parkinson’s disease and healthy controls who:

  1. Weigh 110 pounds or more
  2. Do not have a currently diagnosed autoimmune disease
  3. Have not taken immunosuppressing drugs within 30 days
  4. Do not have a history of severe orthostatic hypotension
  5. Do not currently use anticoagulants
  6. Do not have a history of cancer (except skin cancer)
  7. Do not have a history of heart or lung problems
  8. Do not have a history of bleeding condition or blood disease

Compensation

Provided    $35

Age Range

Age Range 45 or older

Apply for this Trial

Your information will not be published.

All fields are required.

Featured Quote

Save now, read later.

Latest Updates

view all